Aurora Names Seasoned Global CPG Executive to Lead Australia and New Zealand

Rhea-AI Summary

Aurora Cannabis (NASDAQ: ACB) named Kerry Miller as Managing Director for Australia and New Zealand, effective January 15, 2026. Miller is a 35-year consumer packaged goods executive with a 25-year tenure at Reckitt Benckiser and nearly 10 years at Unilever.

The company said Miller will drive growth in the Australia and New Zealand markets, leveraging experience leading global teams and large transformation programs across Australia, UK, USA, Europe, Africa, Middle East and Asia. Miller stated he aims to accelerate innovation, strengthen partnerships, and expand access to medical cannabis for patients and stakeholders in the region.

Key Figures

Industry experience 35 years Consumer packaged goods executive career length

Reckitt Benckiser tenure 25 years Career duration at Reckitt Benckiser

Unilever tenure nearly 10 years Career duration at Unilever

Start date January 15, 2026 Effective date as Managing Director for Australia and New Zealand

Market Reality Check

$4.60 Last Close

Volume Volume 957,386 vs 20-day average 877,867 (relative volume 1.09x) suggests typical interest into this leadership update. normal

Technical Shares at $4.60 were trading below the 200-day MA of $4.86, and about one-third under the 52-week high of $6.91.

Peers on Argus

Peers showed mixed moves, with OGI up 1.23%, LFCR down 1.8%, IRWD down 6.7%, and others flat or modestly lower. This pattern points to stock-specific rather than sector-driven dynamics around this executive appointment.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 02	Distribution deal	Positive	-1.1%	Leafio appointed wholesaler for Aurora medical cannabis brands in Australia.
Nov 05	Earnings results	Positive	-1.8%	Q2 2026 revenue and EBITDA growth with improved margins and cash position.
Oct 22	Investor call	Neutral	+1.2%	Scheduled conference call to discuss upcoming Q2 2026 financial results.
Sep 18	Facility investment	Positive	+3.8%	Multi-year upgrades to Leuna EU-GMP facility to expand capacity and quality.
Sep 09	Education platform	Positive	+4.3%	Launch of English Physician Experience Platform with 130+ case studies.

Pattern Detected

Recent strategic and operational announcements (German facility investment, education platform launch) saw positive price reactions, while the earnings beat and a distribution partnership were followed by modest declines, indicating that good fundamental news has not always translated into immediate upside.

Recent Company History

Over the last few months, Aurora has focused on expanding its global medical cannabis footprint and infrastructure. On Sep 09, it launched the Physician Experience Platform, followed by a multi-year investment in its EU-GMP facility in Germany on Sep 18. An investor call on Oct 22 preceded strong Q2 2026 results reported on Nov 05. A distribution partnership in Australia on Dec 02 further built that region. Today’s leadership appointment for Australia and New Zealand fits into this ongoing international growth and commercialization strategy.

Market Pulse Summary

This announcement adds an experienced 35-year consumer packaged goods leader to oversee Aurora’s Australia and New Zealand operations starting January 15, 2026. It follows recent initiatives in the region, including the Leafio distribution partnership and the rollout of the Physician Experience Platform. Investors may watch for concrete metrics such as regional revenue contributions, margin trends, and further operational updates to assess how this leadership change translates into growth and market share over time.

AI-generated analysis. Not financial advice.

NASDAQ | TSX: ACB

EDMONTON, AB, Dec. 8, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Kerry Miller, a 35-year consumer packaged goods executive, as Managing Director for Australia and New Zealand, effective January 15, 2026. Kerry will be instrumental in driving growth in these key markets, drawing on decades of global experience in fast moving, regulated industries.

"I'm excited to join Aurora at an inflection point in the company's global leadership and to work alongside a team dedicated to expanding access to medical cannabis. I look forward to accelerating innovation, strengthening partnerships, and delivering meaningful value to patients and stakeholders across Australia and New Zealand," said incoming Managing Director for Australia and New Zealand, Kerry Miller.

Kerry joins Aurora with an extensive career in consumer-packaged goods, anchored by a successful 25-year tenure at Reckitt Benckiser and nearly 10 years at Unilever. Throughout his career, he held progressive roles, leading global initiatives, including major transformation programs in Australia, UK, USA, Europe, Africa, Middle East and Asia. Kerry joins Aurora with a wealth of experience in leading global teams to deliver significant topline growth, margin improvement and expanded market share.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information 

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the appointment of a new Managing Director for Australia and New Zealand, expectations for continued growth in the Australian and New Zealand cannabis markets and the Company's plans for accelerating innovation, strengthening partnerships, and delivering meaningful value to patients and stakeholders across Australia and New Zealand.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-names-seasoned-global-cpg-executive-to-lead-australia-and-new-zealand-302634676.html

SOURCE Aurora Cannabis Inc.

FAQ

Who is the new Managing Director for Aurora (ACB) in Australia and New Zealand and when does their role start?

Kerry Miller is the new Managing Director for Australia and New Zealand, starting January 15, 2026.

What is Kerry Miller's background joining Aurora (ACB) for Australia and New Zealand?

Kerry Miller has 35 years in consumer packaged goods, including ~25 years at Reckitt Benckiser and nearly 10 years at Unilever, leading global transformation programs.

What responsibilities will Kerry Miller have as Aurora (ACB) Managing Director for Australia and New Zealand?

He will drive regional growth, accelerate innovation, strengthen partnerships, and expand access to medical cannabis for patients and stakeholders.

Does the announcement include financial guidance or earnings impact for Aurora (ACB)?

No financial figures, guidance, or earnings impacts were included in the announcement.

How does Aurora (ACB) describe Kerry Miller's international experience relevant to Australia and New Zealand?

Aurora notes Miller led programs across Australia, UK, USA, Europe, Africa, Middle East and Asia and delivered topline growth, margin improvement and expanded market share.